The Launching of Levramax ( Levetiracetam ) in Damascus

Saturday, March 10, 2012

Under the slogan of Ibn Al Haytham Pharmaceutical Industries “Partners in Health “and as an assurance of the partnership with doctors and the keen on to provide the appropriate medicines for better quality of life for patients. The company presented Levramax“the constituent is Levetiracetam“which is a new anti-epileptic drug that it wasn’t available in the Syrian Market.

The company organized an important launching event for Levramax:

on Saturday 10/03/2012 at Four Seasons hotel in Damascus, in which Dr. Ahmad Khalifeh – president of Syrian Chapter of Epilepsy and Syrian Society of Neurosciences – presented a lecture under the title “ Selection of AEDs “ . A large number of neurologists attended the lecture. Dr. Ahmad talked about antiepileptic drugs that are available in Syria in addition to their characteristics and the importance of Levetiracetam which is considered to be a new distinguished antiepileptic drug and which achieves an important balance between safety and efficacy.

The lecture was followed by a show about antiepileptic drugs market and Levramax characteristics ‘merits“ in which the meeting was enriched by a discussion and some important interventions of attendance.

This lectures come in the range of launching Levramax drug which is presented by Ibn Al Haytham for the first time in Syria, as an enhancement of its followed scientific field and an emphasis of a continuation partnership with neurologists.